News – Page 1067 – Endpoints News

Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on 'big things' in M&A — analyst

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Moderna boosts unicorn status with a whopping $500M raise and $7B valuation

8 years ago

UCB, investors back a neurosciences startup called Syndesi; Germany's Biofrontera increases US IPO pricing range

8 years ago

Think your odds of R&D success are miserable? MIT’s Andrew Lo might have a surprise for you

8 years ago

Nuclear scare to fuel anti-radiation drug sales? PTx buys ex-Sanofi drug just in case

8 years ago

Puma touts its latest advances in a basket trial for Nerlynx, as Europeans appear ready to reject the drug

8 years ago

Roche silently scraps two one-time blockbuster hopefuls as $725M Seragon deal craters

8 years ago

With a potential cure for lysosomal storage disorders in hand, Avrobio raises $60M to back gene therapy pipeline

8 years ago

Vertex execs whip up a cheer from the analysts after hedging their bet by picking their two top triples for PhIII

8 years ago

NIH, Fox Foundation allies with biopharmas on $24M Parkinson's project; FDA accepts Theravance/Mylan NDA for COPD ...

8 years ago

Startup with Johns Hopkins roots raising $40.5 million to develop cancer metabolism drugs

8 years ago

Analysis: Pfizer tallies an impressive array of late-stage catalysts for cancer, gene therapies and more

8 years ago

Restless Seattle Genetics snaps up a pivotal-stage cancer drug with $614M Cascadian buyout pact

8 years ago

Focused on blockbuster indications, Sage touts evidence that 217 could work on insomnia

8 years ago

A transpacific biotech startup combines Asian investors and some seriously trendy science out of MIT

8 years ago

Brain damage cases force an FDA hold on Bellicum's lead cell therapy -- shares tank

8 years ago

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

8 years ago

Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences

8 years ago

Sunovion scores on PhIII Parkinson's study, shooting for showdown with Acorda; Puma out-licenses neratinib to Israeli ...

8 years ago

Gene therapy pioneer James Wilson sounds an alarm on high-dose AAV studies following toxic reactions in monkeys

8 years ago

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

8 years ago

Merck R&D chief Roger Perlmutter offers some heavyweight R&D glam to a little upstart biotech out to cure Duchenne MD

8 years ago

First page Previous page 1064 1065 106610671068 1069 1070 Next page Last page